Hopefully, Rosetta's expanding knowledge concerning the relationship between microRNAs and colon cancer will result in a world-class screening test for the disease.

Obviously, no company should ever provide a guarantee on commercializing a product such as this due to unexpected outcomes that sometimes occur with scientific discovery.

I have to believe that Rosetta will end up being an expert on the relationship between microRNAs and colon cancer.